ATE135916T1 - Hirnaktivitätfördernde zubereitungen - Google Patents

Hirnaktivitätfördernde zubereitungen

Info

Publication number
ATE135916T1
ATE135916T1 AT92308053T AT92308053T ATE135916T1 AT E135916 T1 ATE135916 T1 AT E135916T1 AT 92308053 T AT92308053 T AT 92308053T AT 92308053 T AT92308053 T AT 92308053T AT E135916 T1 ATE135916 T1 AT E135916T1
Authority
AT
Austria
Prior art keywords
brain activity
activity promoting
cerebral performance
promoting preparations
brain
Prior art date
Application number
AT92308053T
Other languages
English (en)
Inventor
Joachim Bormann
Wolfgang Schatton
Ruediger Koch
Roman Goertelmeyer
Lothar Demisch
Original Assignee
Merz & Co Gmbh & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz & Co Gmbh & Co filed Critical Merz & Co Gmbh & Co
Application granted granted Critical
Publication of ATE135916T1 publication Critical patent/ATE135916T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/385—Concentrates of non-alcoholic beverages
    • A23L2/39—Dry compositions
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/02—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation containing fruit or vegetable juices
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT92308053T 1991-09-06 1992-09-04 Hirnaktivitätfördernde zubereitungen ATE135916T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/755,814 US5262162A (en) 1991-09-06 1991-09-06 Cerebral-activating extract

Publications (1)

Publication Number Publication Date
ATE135916T1 true ATE135916T1 (de) 1996-04-15

Family

ID=25040758

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92308053T ATE135916T1 (de) 1991-09-06 1992-09-04 Hirnaktivitätfördernde zubereitungen

Country Status (11)

Country Link
US (1) US5262162A (de)
EP (1) EP0531155B1 (de)
JP (1) JPH05194247A (de)
KR (1) KR100256452B1 (de)
AT (1) ATE135916T1 (de)
CA (1) CA2077589A1 (de)
DE (1) DE69209414T2 (de)
DK (1) DK0531155T3 (de)
ES (1) ES2086666T3 (de)
GR (1) GR3020121T3 (de)
TW (1) TW217989B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE204159T1 (de) * 1995-05-17 2001-09-15 Peter Greither Verfahren zum herstellen eines brausepräparats und brausepräparat
US5747006A (en) * 1997-05-14 1998-05-05 Amway Corporation Skin whitener composition containing acerola cherry fermentate
US5866585A (en) * 1997-05-22 1999-02-02 Synchroneuron, Llc Methods of treating tardive dyskinesia using NMDA receptor antagonists
US6057373A (en) * 1997-05-22 2000-05-02 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists
ATE214285T1 (de) * 1997-10-27 2002-03-15 Gergely Gerhard Brausezubereitung mit pflanzenextrakt
US6294583B1 (en) 1998-01-13 2001-09-25 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders
US5952389A (en) * 1998-01-13 1999-09-14 Synchroneuron Methods of treating tardive dyskinesia and other movement disorders
EP1052983A2 (de) * 1998-01-27 2000-11-22 Thomas N. Thomas Verwendung eines mao-a oder mao-b inhibitors zur behandlung der gefässerkrankungen
US6184247B1 (en) 1999-05-21 2001-02-06 Amway Corporation Method of increasing cell renewal rate
US6413558B1 (en) 1999-07-19 2002-07-02 The Proctor & Gamble Co. Compositions, kits, and methods for providing and maintaining energy and metal alertness
DE102004041270A1 (de) * 2004-08-26 2006-03-02 Merz Pharma Gmbh & Co. Kgaa Ein Kapillar- Wirksystem enthaltende Zusammensetzungen mit anwendungsbezogener Differenzierbarkeit und deren Verwendung
PT2608798E (pt) * 2010-08-27 2015-03-26 Finzelberg Gmbh & Co Kg Extractos vegetais de sideritis e sua utilização para aumentar o desempenho cognitivo
JP5788065B2 (ja) * 2013-07-14 2015-09-30 アシロス・エ／エス リベス種から誘導可能な新たな生物活性アルカロイドおよびアルカロイド画分
CN107250340B (zh) 2014-09-16 2021-05-07 罗伯特·布洛西亚 源自基于龙舌兰的烈酒的能量饮品和其他营养辅助物
EP3675890A4 (de) * 2017-08-28 2021-11-03 Vitality Wellness (NZ) Limited Verbesserungen in der igf-1-analyse, anpassung und krankheitsverwaltung bei nicht-neurologischen und/oder neurologischen erkrankungen
EP3886612A4 (de) 2018-11-26 2022-08-17 Roar Holding LLC Verfahren zur verbesserung der getränkequalität
US11839622B1 (en) 2020-01-15 2023-12-12 Randall Lewarchik Consumable nutraceutical composition
WO2023163606A1 (en) * 2022-02-28 2023-08-31 Arepa Ip Limited Bioactives and their uses

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR92301E (fr) * 1963-08-09 1968-10-25 Chibret Lab Perfectionnements apportés aux procédés pour l'obtention de glucosides notamment de glucosides d'anthocyanes
FR6760M (de) * 1967-05-30 1969-03-03
ATE24266T1 (de) * 1982-04-16 1987-01-15 Nestle Sa Lipidhaltige zusammensetzung fuer die orale, enterale oder parenterale ernaehrung.
GB2147911B (en) * 1983-10-14 1987-10-07 Nestle Sa A process for the preparation of fatty substances
FR2583640A1 (fr) * 1985-06-24 1986-12-26 Berdal Pascal Compositions pharmaceutiques a visee vasculotrope et antisclereuse
GB2183635B (en) * 1985-10-11 1990-01-24 Peter Jowett Glyceride ester of gamma-linolenic acid
GB8714772D0 (en) * 1987-06-24 1987-07-29 Efamol Ltd Essential fatty acid compositions
FR2622453A1 (fr) * 1987-11-04 1989-05-05 Vaillant Defresne Laboratoire Composition sous forme de gel transparent contenant des grains ou des particules de plantes fraiches ou seches, son procede de preparation et utilisation en cosmetologie, en pharmacie et en hygiene

Also Published As

Publication number Publication date
JPH05194247A (ja) 1993-08-03
EP0531155A1 (de) 1993-03-10
KR100256452B1 (ko) 2000-05-15
US5262162A (en) 1993-11-16
GR3020121T3 (en) 1996-08-31
TW217989B (de) 1993-12-21
DK0531155T3 (da) 1996-06-10
EP0531155B1 (de) 1996-03-27
DE69209414T2 (de) 1996-12-05
CA2077589A1 (en) 1993-03-07
ES2086666T3 (es) 1996-07-01
DE69209414D1 (de) 1996-05-02

Similar Documents

Publication Publication Date Title
ATE135916T1 (de) Hirnaktivitätfördernde zubereitungen
Barsky Amplification, somatization, and the somatoform disorders.
Turner et al. Depression and disability: The stress process in a chronically strained population.
FI911986A (fi) Farmaceutiska foereningar.
ATE100322T1 (de) Verwendung von uridin zur behandlung nervoeser stoerungen.
SV1998000138A (es) Uso de aminometil-cromanos sustituidos para el impedimento de la degeneracion neuronal y para el estimulo de la regeneracion neuronal ref.lea 32408
EP0267676A3 (de) Verwendung von 1,3-Di-n-butyl-7-(2-oxypropyl)xanthin zur Behandlung von zerebrovaskulären oder mit zerebraler Senilität assoziierten Störungen, von peripherer Gefässkrankheit und proliferativen Hautkrankheiten
Caplan Population-oriented psychiatry.
ATE113478T1 (de) Verwendung antigener substanzen zur prophylaxe oder therapie von störungen und krankheiten im verdauungstrakt von tieren und menschen.
EP0383171A3 (de) 2,3,23-Trihydroxy-urs-12-en Derivate zur Behandlung von Kognitiven Störungen
HUP9701606A2 (hu) Szulbutiamin alkalmazása bizonyos pszichomotoros és pszichointellektuális rendellenességek kezelésére használható gyógyszerkészítmények előállítására
Menon et al. Sertraline and liver toxicity in the elderly.
Dilley et al. Psychological complications of AIDS.
Dawe et al. Effects of a xanthine derivative, oxpentifylline, on certain psychological parameters of behaviour and performance
Ratanova EMOTIONAL ASSESSMENT OF AUDITORY-STIMULI OF DIFFERENT INTENSITY
Manthorpe Holding hands and resolving grief.
MY118760A (en) Methods for the prevention and treatment of gastrointestinal disorders caused or mediated by algae of cyanobacteria
PE37498A1 (es) Composiciones para la prevencion y tratamiento de trastornos gastrointestinales
Gambini et al. Neurofunctional assessment of functional CNS disorders: Neuropsychological characteristics of hemispheric functioning as related to drug treatment in schizophrenia.
ATE291919T1 (de) Verwendung von adatanserin zur behandlung von akuten neurodegenerativen erkrankungen
谌剑飞 et al. HEMORRHEOLOGICAL STUDY ON THE EFFECT OF ACUPUNCTURE IN TREATING CEREBRAL INFARCTION
Stolyarova et al. Experimental use of selective monoamine oxidase inhibitors in the treatment of parkinsonism patients.
Hori Applications of the Bi-Digital O-Ring Test for patients with TMD
DE69626260D1 (de) Zusammensetzungen zur Vorbeugung und Behandlung von urogenitalen Störungen, die Wismut enthalten
周荣兴 et al. THE EFFECT OF ACUPUNCTURE ON THE PHAGOCYTIC ACTIVITY OF HUMAN LEUKOCYTES

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee